Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Man-Fung Yuen

Showing results (51-60 of 529) with videos related to

Pageof 53
Sort By:
Journal of Hepatology|November 8, 2024
Reply to: "Prediction of HBsAg loss after cessation of entecavir therapy"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology|November 8, 2024
Reply to: "Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Lancet (London, England)|December 31, 2003
Viral hepatitis CThierry Poynard, Man-Fung Yuen, Vlad Ratziu, et al.
Lancet (London, England)|December 31, 2003
Viral hepatitis BChing Lung Lai, Vlad Ratziu, Man-Fung Yuen, et al.
World Journal of Gastroenterology|March 20, 2008
Natural history of hepatitis-related hepatocellular carcinomaDavid-Yiu-Kuen But, Ching-Lung Lai, Man-Fung Yuen
Journal of Hepatology|December 26, 2024
Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Gut and Liver|March 29, 2019
New Biomarkers of Chronic Hepatitis BLung-Yi Mak, Wai-Kay Seto, James Fung, et al.
Clinical and Molecular Hepatology|November 21, 2024
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis BSaisai Zhang, Lung-Yi Mak, Man-Fung Yuen, et al.
Clinical and Molecular Hepatology|November 30, 2022
Screening strategy for non-alcoholic fatty liver diseaseSaisai Zhang, Lung-Yi Mak, Man-Fung Yuen, et al.
Expert Opinion on Emerging Drugs|March 5, 2016
Emerging drugs for the treatment of hepatitis BJames Fung, Ching-Lung Lai, Wai-Kay Seto, et al.
Pageof 53

Showing results (51-60 of 529) with videos related to

Sort By:
Pageof 53
Journal of Hepatology|November 8, 2024
Reply to: "Prediction of HBsAg loss after cessation of entecavir therapy"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology|November 8, 2024
Reply to: "Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Lancet (London, England)|December 31, 2003
Viral hepatitis CThierry Poynard, Man-Fung Yuen, Vlad Ratziu, et al.
Lancet (London, England)|December 31, 2003
Viral hepatitis BChing Lung Lai, Vlad Ratziu, Man-Fung Yuen, et al.
World Journal of Gastroenterology|March 20, 2008
Natural history of hepatitis-related hepatocellular carcinomaDavid-Yiu-Kuen But, Ching-Lung Lai, Man-Fung Yuen
Journal of Hepatology|December 26, 2024
Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Gut and Liver|March 29, 2019
New Biomarkers of Chronic Hepatitis BLung-Yi Mak, Wai-Kay Seto, James Fung, et al.
Clinical and Molecular Hepatology|November 21, 2024
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis BSaisai Zhang, Lung-Yi Mak, Man-Fung Yuen, et al.
Clinical and Molecular Hepatology|November 30, 2022
Screening strategy for non-alcoholic fatty liver diseaseSaisai Zhang, Lung-Yi Mak, Man-Fung Yuen, et al.
Expert Opinion on Emerging Drugs|March 5, 2016
Emerging drugs for the treatment of hepatitis BJames Fung, Ching-Lung Lai, Wai-Kay Seto, et al.
Pageof 53